Clinical trial

iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray

NCT03192501

StatusRECRUITING

Study typeOBSERVATIONAL

Start date2017-07-01

PhaseN/A

Study timeline

Study start (actual)2017-07-01Date precision: day

Registry last updated2024-06-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Cancerunresolved

Gene Abnormalityunresolved

Gene Product Sequence Variationunresolved

Cancerunresolved

Interventions

inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.DRUG

Sponsors & collaborators

Second Affiliated Hospital of Guangzhou Medical Universitylead sponsor

The First Affiliated Hospital of Guangzhou Medical Universitycollaborator

Sun Yat-sen Universitycollaborator

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03192501 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.